Not Signed In -
Morphine ER |
Avinza; Kadian; MS Contin; Oramorph SR |
Clinical Trial: Bioavailability and Effectiveness of Transdermally Administered Morphine
This study is currently recruiting patients.
Verified by Alberta Cancer Board July 2005
|
Purpose
Patients will participate in two arms of the trial, one of which will be morphine administered transdermally, and after a 3 day wash out period, morphine administered subcutaneously. Blood draws will be done after both dosing in order to comapre blood legels of morphine by the different routes.
| Condition | Intervention | Phase |
|---|---|---|
| Cancer related pain Stable Baseline Pain Currently Taking Opioids | Drug: morphine | Phase I |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Bio-availability Study
Further Study Details:
Primary Outcomes: detectable morphine levels in serum
Expected Total Enrollment: 6
Expected Total Enrollment: 6
Study start: July 2003; Expected completion: July 2007
Last follow-up: July 2007; Data entry closure: July 2007
Patients will participate in two arms of the trial, one of which will be morphine administered transdermally, and after a 3 day wash out period, morphine administered subcutaneously. Blood draws will be done after both dosing in order to comapre blood legels of morphine by the different routes
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- chronic cancer pain minimum baseline pain of 3/10 no change in medications over 3 days prior to study period ability to give informed consent willingness to undergo repeated blood sampling
Exclusion Criteria:
- use of morphine or codeine in 3 days prior to study known sensitivity to morphine prior anaphylactic reaction to any opiod clincially significant anemia
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00125684
Carla Stiles 403-210-8243 carla.stiles@calgaryhealthregion.ca
Canada, Alberta
Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada; Recruiting
Rachel Syme, PhD
Study chairs or principal investigators
Neil Hagen, Principal Investigator, Alberta Cancerboard
More Information
Study ID Numbers: 10181
Last Updated: August 1, 2005
Record first received: August 1, 2005
ClinicalTrials.gov Identifier: NCT00125684
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-02
Last Updated: August 1, 2005
Record first received: August 1, 2005
ClinicalTrials.gov Identifier: NCT00125684
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-02
email this page
print this page
bookmark this page
feedback on this page
